Home

Bringing LSPR Nanotechnology to In Vitro Diagnostics and Life Sciences

LamdaGen has developed a digital LSPR nanotechnology detection platform that enables diagnostic sensitivities and precise quantitation at levels far beyond the expected. Our patented nano-structured Localized Surface Plasmon Resonance technology (LSPR nanotechnology) produces highly robust biosensors in the form of metallic thin films that exhibit remarkable diagnostic detection capabilities into the low to sub-femtomolar range.

Plasmonic ELISA™ technology facilitates diagnostic detection limits into the femtomolar range, up to 4 logs more sensitive than conventional ELISA

Troponin I (cTnI) Ap Note: Read More ›

 

Platform for Next Generation Diagnostics: Read More ›

 

Plasmonic ELISA™

Ideally suited for In-Vitro and POC diagnostic systems, LamdaGen’s Plasmonic ELISA platform is precise, highly sensitive and rapid.

Learn More ›

LightPath™ S4

LamdaGen’s LightPath S4 system performs highly sensitive label-free, real-time monitoring and characterization of biomolecular interactions.

Learn More ›

LSPR Biosensors

LamdaGen’s metallic thin-film LSPR-based Optical Biosensors for research and development in the areas of Life Science and Cleantech.

Learn More ›

News & Literature

ACS Nano Publication: Cellular Functional Immunoanalysis Using LamdaGen LSPR Biosensors Read More ...

Abaxis and LamdaGen Corporation Enter Into R&D Diagnostic Collaboration Read More ...

LamdaGen Develops Novel, Highly Sensitive cTnI Assay Utilizing HyTest Anti-cTnI Antibodies and Troponin I-T-C Complex Read More ...

More News >